The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis.

Trial Profile

The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Feb 2013 Additional lead trial centre and trial company Novartis added as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date changed from 1 Nov 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top